Skip to content

QNCX - Quince Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchQ

Quince Therapeutics, Inc.

QNCX · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

Q

QNCXQuince Therapeutics, Inc.

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $910.00
52-wk low: $15.10
Prev close: $502.73
Mkt cap: $32.7M
Beta: 1.26
P/B: 2.2x

Smart money

4 funds hold a position.

Real smart money

Funds holding this stock

4 holders

Combined position$13.9M

BA
Balyasny
Dmitry Balyasny · Q2 2026 13F
$12.6M
position
MI
Millennium
Israel Englander · Q2 2026 13F

Earnings

Reported Aug 10, 2026

Earnings came in 63.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $33M

Valuation

P/B2.21

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: QNCX
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $32.66M
Beta: 1.26

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-153.8%

$1.3M

position

BR

BlackRock

Q2 2026 13F

$31K

position

1 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 1 holders

Coverage gaps for QNCX

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$12.31+63.0%

-$33.26 expected

Next report

What the street expects next

EPS expected

-$0.83

-$0.83 to -$0.83

Revenue expected

$0.00

5 analysts

Estimate drift

+0.56

Change in 30 days

-153.8%

ROA-31.5%

Growth

Beta1.26